Published in Cancer Weekly, March 28th, 2000
"Polymorphic epithelial mucin (PEM or MUCI) is being studied as a vaccine substrate for the immunotherapy of patients with adenocarcinoma," stated S. von Mensdorff-Pouilly and colleagues, Vrije University Amsterdam, The Netherlands. "The present study analyzes the incidence of naturally occurring MUC1 antibodies in early breast cancer patients and relates the presence of these antibodies in pretreatment serum to outcome of disease."
von Mensdorff-Pouilly et al. published the results of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.